|
摘要：
|
|
摘要：代谢相关脂肪性肝病（metabolic associated fatty liver disease，MAFLD）是一
种受多种机制（包括代谢、遗传、环境和肠道微生物因素）调节的复杂疾病。随时间
推移，其发病率呈上升趋势。近年来，研究人员积极开展有关MAFLD的研究，新的
靶点和药物不断被发现。然而目前尚无美国食品药品监督管理局批准的特效药物治疗
MAFLD，现有的标准治疗依赖改善生活方式，主要包括饮食和运动。本文对MAFLD
的发病机制和治疗进展进行综述，以期为临床医生提供关于MAFLD治疗的新方向。
|
|
Abstract: Metabolic associated fatty liver disease (MAFLD) is a complex disease regulated
by multiple mechanisms, including metabolic, genetic, environmental and gut microbiological
factors. The incidence has shown an increasing trend. In recent years, many studies on MAFLD
have been actively carried out, remarkable results have been achieved, and new targets and
drugs have been discovered. However, there are currently no American Food and Drug
Administration-approved specific drugs for the treatment of MAFLD, and the existing standard
treatment relies on improving lifestyle, mainly including diet and exercise. The purpose of this
review is to provide an overview of the pathogenesis and progress in the treatment of MAFLD
and to provide clinicians with new directions on the treatment of MAFLD.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|